ClinicalTrials.gg
RecruitingNCT03475498Updated Oct 2, 2025

A Major Determinant Focused on the ECG or Echocardiogram for PICM and Its Clinical Outcome (PICM Syndrome)

An observational study in Pacemaker Complication, sponsored by Eulji University Hospital. Recruiting at 3 sites in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Eulji University Hospital · Observational

From the registry’s dates

  • Started Jan 2018; still recruiting 8 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
20 Years and older
Sex
All
01

Study summary

Chronic right ventricular pacing has a deleterious effect on left ventricular (LV) function, namely pacing-induced cardiomyopathy (PICM). Several parametes make difference of effect on the occurrence of PICM and its subsequent clinical outcomes. In particular, recognition of a major determinant focused on the ECG or echocardiographic parameters including strain or genetic factor for occurrence of PICM may lead to better identification of patients at high risk. Investigators prospectively enroll a participant with documented high risk of PICM and clinically follow-up to idenify clinical impact of PICM (PICM syndrome) over a long period of time.

Read the detailed description

Investigators investigate a major determinant focused on the ECG or echocardiogram or genetic factor to predict the PICM after implantation of pacemaker. Not only QRS duration and mechanical strain but also genetic factor could be also investigated to predict the occurrence of PICM before diagnosis fo PICM

02

Conditions studied

  • Pacemaker Complication
03

In context

Lead sponsor

Eulji University Hospital is the lead sponsor of 10 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will enroll at least 1000 device patients from multi-centers in order to identify and assess a determinant of PICM and its clinical outcomes (PICM syndrome)

Eligibility criteria

Inclusion Criteria: mandatory (1 and 2) and optional (3 or 4)

  1. Willng to participate in the study and able to sign
  2. Undertaken and echocardiogram including strain before and after device implantation

Exclusion Criteria:

  1. Less than 18 years of age
  2. Being pregnant or plan to become pregnant
  3. Advanced heart failure waiting in heart transplantation
  4. Have a of less than 1 year
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Heart failure diagnosis and treatment

    Occurrence of heart failure symptom, diagnosis and treatment

    Time frame: 5 years

Secondary outcomes

  1. Atrial and Ventricular arrhythmia diagnosis, heart failure admisssion and all-caused mortality

    Occurrence of atrial, ventricular arrhythmia, hear failure admission and all-cause mortality

    Time frame: 5 years

07

Study locations

3 of 3 sites recruiting
  • Chung-Buk University Hospital
    Chungju, South Korea
    Recruiting
    • Deain Lee, M.D. · Contact
  • Chung-Nam University Hospital
    Daejeon, South Korea
    Recruiting
    • Jun Hyung Kim, MD. PhD. · Contact
  • Chung-Ang University Hospital
    Seoul, South Korea
    Recruiting
08

References and documents

Publications

  • Kim JH, Kang KW, Chin JY, Kim TS, Park JH, Choi YJ. Major determinant of the occurrence of pacing-induced cardiomyopathy in complete atrioventricular block: a multicentre, retrospective analysis over a 15-year period in South Korea. BMJ Open. 2018 Feb 8;8(2):e019048. doi: 10.1136/bmjopen-2017-019048. PubMed 29439074 ↗
  • Chin JY, Kang KW, Park SH, Choi YJ, Jung KT, Lee S, Youn HJ. Pre-implant global longitudinal strain as an early sign of pacing-induced cardiomyopathy in patients with complete atrioventricular block. Echocardiography. 2021 Feb;38(2):175-182. doi: 10.1111/echo.14942. Epub 2021 Jan 6. PubMed 33406280 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2018 (actual). Primary completion is estimated for Feb 2027, 108 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2018
First posted
Mar 23, 2018
StartActual
Jan 30, 2018
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2028
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03475498
Lead sponsor
Eulji University Hospital
Collaborators
Chungnam National University Hospital, Chungbuk National University Hospital, Dankook University, Chung-Ang University Hospital
Responsible party
Ki-Woon Kang, MD (Professor, Chung-Ang University Hospital) — Principal investigator
First posted
Mar 23, 2018
Start date
Jan 30, 2018
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Oct 2, 2025

Study contacts

Ki-Woon Kang, MD., PhD.
Contact
kwkang0115@gmail.com
81 10 4492 2136
Hyu Ryung Cho
Contact
KI-Woon Kang, MD PhD
principal investigator · Chung-Ang University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion